Vadalà Giuseppe, Madaudo Cristina, Fontana Alessandra, Sucato Vincenzo, Bicelli Gioele, Maniscalco Laura, Parlati Antonio Luca Maria, Panarello Giovanna, Sciacca Sergio, Pilato Michele, Cipriani Manlio, Galassi Alfredo Ruggero
Division of Cardiology, University Hospital "P. Giaccone", Via Del Vespro 129, 90100 Palermo, Italy.
Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, 90127 Palermo, Italy.
J Cardiovasc Dev Dis. 2025 Mar 19;12(3):105. doi: 10.3390/jcdd12030105.
Gastrointestinal bleeding (GIB) is a common complication of left ventricular assist device (LVAD) support. The UTAH bleeding risk score (UBRS) is the only dedicated GIB prediction model, but its efficacy has not been confirmed in an external validation cohort. Furthermore, the reliability of other bleeding risk scores, such as ARC-HBR and HASBLED, has never been tested in this specific population. This study aims to validate the UBRS and compare its accuracy with the ARC-HBR and HASBLED scores.
Major adverse events (MAEs) and bleeding events of 75 consecutive patients who had undergone LVAD implantation between 2010 and 2021 at a referral hospital for a heart transplant were retrospectively analyzed. The accuracy of the UBRS, ARC-HBR and HASBLED scores was evaluated using a ROC curve model.
At a mean follow-up of 905.9 ± 724 days, 58 (77.3%) patients had an MAE and 28 (37.3%) had a major bleeding event. Out of the 39 major bleeding events, the majority were GI (43%) and intracranial bleeding (33.3%). Compared with patients without major bleeding, those who experienced major bleeding showed a lower survival probability, regardless of the nature of the bleeding (GIB vs. other bleeding events). The UBRS effectively stratified the bleeding risk with an AUC of 0.86. In contrast, the ARC-HBR and HASBLED scores demonstrated lower discriminatory power, with AUCs of 0.61 and 0.52, respectively.
UBRS accuracy was confirmed in our study population. Gastrointestinal bleeding is a common life-threatening complication and one of the main causes of re-hospitalization during VAD support, leading to a lower patient survival probability.
胃肠道出血(GIB)是左心室辅助装置(LVAD)支持治疗的常见并发症。犹他州出血风险评分(UBRS)是唯一专门用于GIB的预测模型,但其有效性尚未在外部验证队列中得到证实。此外,其他出血风险评分,如ARC-HBR和HASBLED的可靠性从未在这一特定人群中进行过测试。本研究旨在验证UBRS,并将其准确性与ARC-HBR和HASBLED评分进行比较。
回顾性分析了2010年至2021年期间在一家心脏移植转诊医院接受LVAD植入的75例连续患者的主要不良事件(MAE)和出血事件。使用ROC曲线模型评估UBRS、ARC-HBR和HASBLED评分的准确性。
平均随访905.9±724天,58例(77.3%)患者发生MAE,28例(37.3%)发生大出血事件。在39例大出血事件中,大多数为胃肠道出血(43%)和颅内出血(33.3%)。与未发生大出血的患者相比,发生大出血的患者生存概率较低,无论出血的性质如何(GIB与其他出血事件)。UBRS有效地分层了出血风险,AUC为0.86。相比之下,ARC-HBR和HASBLED评分的鉴别能力较低,AUC分别为0.61和0.52。
在我们的研究人群中证实了UBRS的准确性。胃肠道出血是一种常见的危及生命的并发症,是VAD支持期间再次住院的主要原因之一,导致患者生存概率降低。